United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. trimmed its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,511 shares of the biotechnology company's stock after selling 2,095 shares during the period. Corebridge Financial Inc. owned 0.11% of United Therapeutics worth $17,822,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in UTHR. Vanguard Group Inc. grew its stake in United Therapeutics by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after buying an additional 32,213 shares during the last quarter. LPL Financial LLC boosted its holdings in United Therapeutics by 122.8% in the fourth quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock worth $5,024,000 after acquiring an additional 7,847 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $429,000. KLP Kapitalforvaltning AS acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $15,278,000. Finally, AXQ Capital LP acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $454,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company's stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,755 shares of company stock valued at $29,792,021 in the last 90 days. 11.90% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Trading Down 0.3 %

UTHR traded down $1.05 during midday trading on Friday, hitting $306.97. 223,177 shares of the company were exchanged, compared to its average volume of 450,767. The company's 50 day simple moving average is $340.06 and its 200 day simple moving average is $355.78. The firm has a market capitalization of $13.79 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period last year, the company earned $4.36 earnings per share. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.